SEC Form 4 · accession 0000899243-19-005963
Kaleido Biosciences, Inc. · KLDO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony G. Quinn
Director
Period of report
Mar 4, 2019
Accepted (ET)
Mar 4, 2019 · 8:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001751299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 4, 2019 | C | 12,853 | — | A | 31,603 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Preferred StockF1 | — | Mar 4, 2019 | C | 25,707 | D | — | — | Common Stock | 12,853 | 0 | D |
Explanation of responses
- F1Each share of Series B Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering.